TGFβ blockade relieves the immunosuppression of cytotoxic CD8+ T cells and NK cells, promotes lineage switching within the CD4+ T cell population, depolarizes immunosuppressive intratumoral myeloid cells and CAFs, and inhibits angiogenesis, leading to tumor regression and long-term immunity. Here, CD8A is linked to neoplasm.